Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Schlumberger NV — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Schlumberger NV trades at $48.95 (market cap $72.69B). The key difference: Schlumberger NV is far larger — about 5.8× Halozyme Therapeutics Inc. Common Stock's market cap, and Schlumberger NV pays a 2.41% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Schlumberger NV for 99 Days on average.
| HALO | SLB | |
|---|---|---|
Market Cap | $12.58B | $72.69B |
Volume | 2,179,278 | 16,228,451 |
Sector | Health | Energy |
52-Week High | $115.22 | $60.10 |
52-Week Low | $61.63 | $31.72 |
Typical Hold Time | 1 Days | 99 Days |
Enterprise Value | $14.49B | $81.42B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SLB trades at $48.98, up 2.13% today, with strong analyst support (85% buy ratings) and a $64.58 consensus price target suggesting 32% upside. Recent contract wins in Saudi Arabia, Oman, and Mozambique expand revenue visibility, though technical indicators show bearish momentum. The company maintains solid profitability with 8.53% net margins and consistent earnings beats in recent quarters.
SLB's multi-year contracts provide stable revenue streams, but declining profit margins and bearish technicals present near-term headwinds. The stock offers value with reasonable valuation multiples (P/E 23.89) and dividend income, though energy sector volatility and execution risks on new projects require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
